7 research outputs found

    Extracting relevant predictive variables for COVID-19 severity prognosis: An exhaustive comparison of feature selection techniques

    Get PDF
    With the COVID-19 pandemic having caused unprecedented numbers of infections and deaths, large research efforts have been undertaken to increase our understanding of the disease and the factors which determine diverse clinical evolutions. Here we focused on a fully data-driven exploration regarding which factors (clinical or otherwise) were most informative for SARS-CoV-2 pneumonia severity prediction via machine learning (ML). In particular, feature selection techniques (FS), designed to reduce the dimensionality of data, allowed us to characterize which of our variables were the most useful for ML prognosis. We conducted a multi-centre clinical study, enrolling n=1548 patients hospitalized due to SARS-CoV-2 pneumonia: where 792, 238, and 598 patients experienced low, medium and high-severity evolutions, respectively. Up to 106 patient-specific clinical variables were collected at admission, although 14 of them had to be discarded for containing ⩾60% missing values. Alongside 7 socioeconomic attributes and 32 exposures to air pollution (chronic and acute), these became d=148 features after variable encoding. We addressed this ordinal classification problem both as a ML classification and regression task. Two imputation techniques for missing data were explored, along with a total of 166 unique FS algorithm configurations: 46 filters, 100 wrappers and 20 embeddeds. Of these, 21 setups achieved satisfactory bootstrap stability (⩾0.70) with reasonable computation times: 16 filters, 2 wrappers, and 3 embeddeds. The subsets of features selected by each technique showed modest Jaccard similarities across them. However, they consistently pointed out the importance of certain explanatory variables. Namely: patient’s C-reactive protein (CRP), pneumonia severity index (PSI), respiratory rate (RR) and oxygen levels –saturation SpO2, quotients SpO2/RR and arterial SatO2/FiO2 –, the neutrophil-to-lymphocyte ratio (NLR) –to certain extent, also neutrophil and lymphocyte counts separately–, lactate dehydrogenase (LDH), and procalcitonin (PCT) levels in blood. A remarkable agreement has been found a posteriori between our strategy and independent clinical research works investigating risk factors for COVID-19 severity. Hence, these findings stress the suitability of this type of fully data-driven approaches for knowledge extraction, as a complementary to clinical perspectives

    Impact of outdoor air pollution on severity and mortality in COVID-19 pneumonia

    Get PDF
    The relationship between exposure to air pollution and the severity of coronavirus disease 2019 (COVID-19) pneumonia and other outcomes is poorly understood. Beyond age and comorbidity, risk factors for adverse outcomes including death have been poorly studied. The main objective of our study was to examine the relationship between exposure to outdoor air pollution and the risk of death in patients with COVID-19 pneumonia using individual-level data. The secondary objective was to investigate the impact of air pollutants on gas exchange and systemic inflammation in this disease. This cohort study included 1548 patients hospitalised for COVID-19 pneumonia between February and May 2020 in one of four hospitals. Local agencies supplied daily data on environmental air pollutants (PM10PM_{10}, PM2.5PM_{2.5}, O3O_3, NO2NO_2, NONO and NOXNO_X) and meteorological conditions (temperature and humidity) in the year before hospital admission (from January 2019 to December 2019). Daily exposure to pollution and meteorological conditions by individual postcode of residence was estimated using geospatial Bayesian generalised additive models. The influence of air pollution on pneumonia severity was studied using generalised additive models which included: age, sex, Charlson comorbidity index, hospital, average income, air temperature and humidity, and exposure to each pollutant. Additionally, generalised additive models were generated for exploring the effect of air pollution on C-reactive protein (CRP) level and SpO2O_2/FiO2O_2 at admission. According to our results, both risk of COVID-19 death and CRP level increased significantly with median exposure to PM10PM_{10}, NO2NO_2, NONO and NOXNO_X, while higher exposure to NO2NO_2, NONO and NOXNO_X was associated with lower SpO2O_2/FiO2O_2 ratios. In conclusion, after controlling for socioeconomic, demographic and health-related variables, we found evidence of a significant positive relationship between air pollution and mortality in patients hospitalised for COVID-19 pneumonia. Additionally, inflammation (CRP) and gas exchange (SpO2O_2/FiO2O_2) in these patients were significantly related to exposure to air pollution

    Predicción de la gravedad de neumonías por SARS-CoV-2 a partir de información clínica y contaminación, mediante inteligencia artificial

    Get PDF
    Introducción La contaminación del aire exterior se ha relacionado con mayor gravedad de las infecciones respiratorias. Por tanto, su inclusión en algoritmos predictivos podrían añadir información para pronosticar la gravedad de neumonías SARS-CoV-2. Material y métodos Estudio observacional longitudinal retrospectivo de cohortes, multicéntrico en 4 hospitales. Se incluyeron ingresos por neumonía SARS-CoV-2 en el primer pico epidémico de COVID-19 (febrero-mayo 2020). Se recogieron hasta 93 variables clínicas, analíticas y radiológicas por cada paciente (sexo, edad, peso, comorbilidades, síntomas, variables fisiológicas en urgencias, sangre, gasometría, etc.). Además, se calcularon los niveles exposición a contaminación por PM10_{10}, PM2.5_{2.5}, O3_{3}, NO2_{2}, NO, NOX_{X}, SO2_{2} y CO en su código postal. En función de la evolución clínica de la neumonía, se definieron 3 niveles de gravedad [Tabla 1]. Para predecir dicha gravedad, se desarrolló un algoritmo de inteligencia artificial (IA), tipo ‘Random Forest’ con balanceo y ajuste automático de sus parámetros internos. El algoritmo se entrenó y evaluó mediante 20 repeticiones de validación cruzada 10-fold (90% entrenamiento, 10% validación), estratificando aleatoriamente por hospital y gravedad. Resultados En los conjuntos de validación, el algoritmo alcanzó una capacidad predictiva (área bajo la curva ROC) promedio AUC=0.834 para gravedad nivel 0, AUC=0.724 para 1 y AUC=0.850 para 2 [Figura 1]. Sin la información de contaminantes, su capacidad predictiva se degradó ligeramente (AUCs = 0.829, 0.722, 0.844; respectivamente). Conclusiones Nuestro algoritmo IA es capaz de predecir de manera satisfactoria la evolución de la gravedad en la neumonía; en particular para los casos más leves y más severos. El algoritmo IA extrae las reglas más relevantes a partir principalmente de la información clínica, analítica y radiológica de cada individuo; no obstante, la incorporación de la exposición a contaminantes mejora ligeramente la capacidad predictiva. El impacto de la contaminación podría estar ya reflejado en las analíticas de sangre, a través de su efecto en los niveles de inflamación del paciente (PCT, PCR, LDH, etc.)

    Impacto cuantitativo de la contaminación en la probabilidad de muerte por neumonía por SARS-CoV-2

    Get PDF
    Introducción La evidencia científica disponible señala que la contaminación del aire exterior podría agravar la severidad de la COVID-19 y por ende, incrementar las probabilidades de fallecimiento. Material y métodos Estudio observacional longitudinal retrospectivo de cohortes, multicéntrico en 4 hospitales: 2 en Bizkaia (1 urbano, 1 urbano-rural), Valencia y Barcelona (urbanos). Se incluyeron ingresos por neumonía SARS-CoV-2 en el primer pico epidémico de COVID-19 (febrero-mayo 2020). Para determinar la exposición a contaminación por PM10_{10} y NO2_{2}, se obtuvieron los datos publicados por los organismos autonómicos de calidad del aire, para 2019 y 1er semestre 2020. Se utilizó un Modelo Aditivo Generalizado (GAM) para estimar el nivel diario de contaminante en cada código postal, en función de las coordenadas geográficas y la altitud de las estaciones de medición [Figura 1]. Para determinar la exposición crónica, se calcularon media y máximo en 2019; la aguda se caracterizó por media y máximo en los 7 días anteriores al ingreso. Se estudió la razón de probabilidades (‘odds ratio’, OR) de muerte frente a supervivencia entre nuestra cohorte. Se modeló mediante un GAM con regresión logística, incorporando como efectos fijos sexo, edad y contaminante; hospital como efecto aleatorio e índice de comorbilidad de Charlson como función suave mediantes splines penalizados. Resultados De los 1548 pacientes reclutados, 243 (15.7%) fallecieron durante su hospitalización y/o 30 días postingreso. Según los modelos [Tabla 1], existe evidencia estadística significativa de que la exposición crónica a PM10_{10} y NO2_{2} incrementan la probabilidad de muerte por neumonía SARS-CoV-2. Compensando por sexo, edad y Charlson -todos factores relacionados positivamente con el OR de muerte- así como por hospital; por cada incremento de 10 μg/m3^{3} en el nivel de PM10_{10} (máximo anual) el OR aumenta en 10.5%, linealmente proporcional al incremento en la contaminación. Mientras, cada 10 μg/m3^{3} más de NO2 (media anual) aumentan OR en 35.7%; cada 10 μg/m3^{3} más en exposición aguda a NO2 (media semana pre-ingreso): 62.9%; y NO2_{2} (máximo semana): 34.4%. Conclusiones Se cuantificaron y compensaron los efectos de los factores sexo, edad, Charlson y hospital. A igualdad de estos, incrementos en la exposición crónica y aguda a PM10_{10} y NO2_{2} aumentan de manera lineal y estadísticamente significativa la probabilidad de muerte por neumonía SARS-CoV-2

    Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma

    No full text
    Background: Pediatric patients with diffuse intrinsic pontine glioma (DIPG) have a poor prognosis, with a median survival of less than 1 year. Oncolytic viral therapy has been evaluated in patients with pediatric gliomas elsewhere in the brain, but data regarding oncolytic viral therapy in patients with DIPG are lacking. Methods: We conducted a single-center, dose-escalation study of DNX-2401, an oncolytic adenovirus that selectively replicates in tumor cells, in patients with newly diagnosed DIPG. The patients received a single virus infusion through a catheter placed in the cerebellar peduncle, followed by radiotherapy. The primary objective was to assess the safety and adverse-event profile of DNX-2401. The secondary objectives were to evaluate the effect of DNX-2401 on overall survival and quality of life, to determine the percentage of patients who have an objective response, and to collect tumor-biopsy and peripheral-blood samples for correlative studies of the molecular features of DIPG and antitumor immune responses. Results: A total of 12 patients, 3 to 18 years of age, with newly diagnosed DIPG received 1×1010 (the first 4 patients) or 5×1010 (the subsequent 8 patients) viral particles of DNX-2401, and 11 received subsequent radiotherapy. Adverse events among the patients included headache, nausea, vomiting, and fatigue. Hemiparesis and tetraparesis developed in 1 patient each. Over a median follow-up of 17.8 months (range, 5.9 to 33.5), a reduction in tumor size, as assessed on magnetic resonance imaging, was reported in 9 patients, a partial response in 3 patients, and stable disease in 8 patients. The median survival was 17.8 months. Two patients were alive at the time of preparation of the current report, 1 of whom was free of tumor progression at 38 months. Examination of a tumor sample obtained during autopsy from 1 patient and peripheral-blood studies revealed alteration of the tumor microenvironment and T-cell repertoire. Conclusions: Intratumoral infusion of oncolytic virus DNX-2401 followed by radiotherapy in pediatric patients with DIPG resulted in changes in T-cell activity and a reduction in or stabilization of tumor size in some patients but was associated with adverse events. (Funded by the European Research Council under the European Union's Horizon 2020 Research and Innovation Program and others; EudraCT number, 2016-001577-33; ClinicalTrials.gov number, NCT03178032.)
    corecore